Le Lézard
Classified in: Health, Business
Subject: PER

Pappas Capital Names Kyle Rasbach as Partner



RESEARCH TRIANGLE PARK, N.C., Jan. 3, 2018 /PRNewswire/ -- Pappas Capital announced today that Kyle Rasbach, PhD, PharmD has joined the firm as a partner. Dr. Rasbach was previously a Vice President with T. Rowe Price, where he was an equity research analyst responsible for pharmaceutical, specialty pharmaceutical and biotechnology investments for funds managed by T. Rowe Price, a global asset management firm. He is expected to play a key role in the investment of Pappas Capital's most recent fund, Pappas Ventures V, which made its initial investment last May and has invested so far in Amplyx Pharmaceuticals, Kezar Life Sciences, Reneo Pharmaceuticals and OrphoMed.

 (PRNewsfoto/Pappas Capital)

"I am thrilled to become part of the Pappas Capital team, whose track record and reputation for building innovative companies I have long admired," said Dr. Rasbach. During his time at T. Rowe Price, he led the firm's IPO investment in Pappas portfolio company CoLucid Pharmaceuticals, which was sold in early 2017 to Eli Lilly for just under $1 billion.

Since 2014, three portfolio companies founded or co-founded by Pappas have been sold to large pharmaceutical companies: CoLucid; Afferent Pharmaceuticals, bought by Merck in 2016 for $500 million upfront and $750 million in milestones; and Lumena Pharmaceuticals, bought by Shire in 2014 for more than $300 million. Over the past five years a dozen Pappas portfolio companies have been acquired or have completed an initial public offering ? among them, Ultragenyx Pharmaceutical (IPO), TESARO (IPO), TYRX (acquired by Medtronic), and Chimerix (IPO). Most recently, in early December portfolio company Rotation Medical was acquired by Smith & Nephew.

"Kyle's deep scientific experience will further position Pappas Capital to identify and nurture the most promising biotech companies," said Managing Partner Art Pappas. "And meanwhile, his extensive background in equity research and public market investing will add an important new dimension to our firm."

Prior to T. Rowe Price, Dr. Rasbach was a Vice President at Cowen and Company, where he covered global pharmaceutical equities. He completed his postdoctoral work in the laboratory of Bruce Spiegelman at Harvard Medical School, where he contributed to numerous high profile publications, including papers in Cell, Cell Metabolism, Nature and PNAS. Dr. Rasbach received his PhD and PharmD from the Medical University of South Carolina, and an MBA from the Citadel.

About Pappas Capital 
Founded in 1994, Pappas Capital invests exclusively in the life sciences sector ? biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures ? across the United States and Canada. Pappas Capital has raised more than $500 million in capital and has guided the launch and/or development of more than 70 companies. For more information about Pappas Capital, please visit www.pappas-capital.com.

CONTACT:   
Ford S. Worthy
fworthy@pappas-capital.com 
919-998-3330

SOURCE Pappas Capital


These press releases may also interest you

at 03:00
SCOTCH PLAINS, N.J., June 22, 2018 /PRNewswire-PRWeb/ -- Owner of Montclair Dental Spa, Dr. Joseph Moussa, recently signed a publishing deal to co-write the forthcoming book titled, The Will to Win, published by CelebrityPress® LLC. The new book is...

at 03:00
Royal DSM, a global science-based company active in health, nutrition and materials, has repurchased 324,894 of its own shares in the period from 15 June 2018 up to and including 20 June 2018 at an average price of ?88.18. This is in accordance...

at 02:00
- Positive recommendation for Dupixent[R] (dupilumab) in Final Appraisal Determination (FAD) paves the way for the first targeted biologic for adults with moderate to severe atopic dermatitis - Atopic dermatitis is the most common type of...

21 jun 2018
India-Based APAC Biotech and US-Based Diakonos Research sign a first-of-its-kind technology transfer and licensing agreement to bring new immunotherapy technology to India as an advancement of immuno-oncology therapeutics for solid tumors.     ...

21 jun 2018
Today, the largest single donation in Mackenzie Health Foundation's history was announced: a $20-million joint gift from the De Gasperis and Kohn families to help build and equip the new Mackenzie Vaughan Hospital. The gift was announced at the City...

21 jun 2018
PharmaEngine Inc. (TWO: 4162) and its corporate partner, Nanobiotix S.A. (Euronext: NANO) announced today that PEP503 (NBTXR3) in combination with radiotherapy met the primary endpoint of pathological Complete Response Rate (pCRR) as compared to...




News published on 3 january 2018 at 11:06 and distributed by: